Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the subject of a number of analyst reports. BMO Capital Markets restated an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, January 8th.

Genmab A/S Trading Down 1.9 %

GMAB opened at $21.72 on Tuesday. The stock’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $24.17. The stock has a market cap of $14.37 billion, a PE ratio of 21.09, a P/E/G ratio of 0.63 and a beta of 0.97. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the firm earned $0.47 EPS. Equities analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. Legacy Wealth Asset Management LLC raised its stake in shares of Genmab A/S by 1.1% in the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after acquiring an additional 471 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after buying an additional 1,121 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after buying an additional 1,236 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.